ID

38947

Description

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine; ODM derived from: https://clinicaltrials.gov/show/NCT01680341

Lien

https://clinicaltrials.gov/show/NCT01680341

Mots-clés

Versions (1)
  1. 15/11/2019 15/11/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

15 novembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Diabetes NCT01680341

Anglais

Eligibility Diabetes NCT01680341

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680341
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
- - type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to visit 2 (randomisation)
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
- - currently treated with iglar (insulin glargine) and up to 3 oral antidiabetic drugs (oads) (metformin, dpp-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase inhibitor). all antidiabetic treatments should have been ongoing for at least 12 weeks prior to visit 2 (randomisation) and doses should have been stable in this period of time
Description

Insulin Glargine | Antidiabetics Oral Quantity | Metformin | Dipeptidyl Peptidase 4 Inhibitors | Sulfonylurea | Glinide | alpha-Glucosidase Inhibitors | Diabetes Therapy Dose Stable

Type de données

boolean

Alias
UMLS CUI [1]
C0907402
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C1527415
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0025598
UMLS CUI [4]
C2917254
UMLS CUI [5]
C0038766
UMLS CUI [6]
C2266929
UMLS CUI [7]
C1299007
UMLS CUI [8,1]
C3274787
UMLS CUI [8,2]
C0178602
UMLS CUI [8,3]
C0205360
- - glycosylated haemoglobin (hba1c) 7.0-10.0% (both inclusive) by central laboratory analysis
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
- - body mass index (bmi) below or equal to 40 kg/m^2
Description

Body mass index

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
- - treatment with glucagon-like peptide 1 (glp-1) receptor agonists or thiazolidinediones (tzds) both within the last 12 weeks prior to visit 2 (randomisation)
Description

GLP-1 Receptor Agonist | Thiazolidinediones

Type de données

boolean

Alias
UMLS CUI [1]
C2917359
UMLS CUI [2]
C1257987
- - stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 24 weeks prior to visit 2 (randomisation)
Description

Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty

Type de données

boolean

Alias
UMLS CUI [1]
C0038454
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
UMLS CUI [3]
C0027051
UMLS CUI [4]
C0002965
UMLS CUI [5]
C0010055
UMLS CUI [6]
C0162577
- - uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmhg and/or diastolic blood pressure above or equal to 100 mmhg
Description

Uncontrolled hypertension Severe | Severe hypertension Untreated | Systolic Pressure | Diastolic blood pressure

Type de données

boolean

Alias
UMLS CUI [1,1]
C1868885
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C4013784
UMLS CUI [2,2]
C0332155
UMLS CUI [3]
C0871470
UMLS CUI [4]
C0428883
- - recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12 months) or hypoglycaemic unawareness as judged by the investigator
Description

Recurrent severe hypoglycemia | Hypoglycaemic episode Severe Quantity | Loss of hypoglycemic warning

Type de données

boolean

Alias
UMLS CUI [1]
C0342316
UMLS CUI [2,1]
C0745153
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C1265611
UMLS CUI [3]
C0342317
- - life-threatening disease (e.g. cancer)
Description

Life threatening illness | Malignant Neoplasms

Type de données

boolean

Alias
UMLS CUI [1]
C3846017
UMLS CUI [2]
C0006826
Retour au début de la page

Similar models

Eligibility Diabetes NCT01680341

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01680341
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Non-Insulin-Dependent Diabetes Mellitus Disease length
Item
- - type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to visit 2 (randomisation)
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Insulin Glargine | Antidiabetics Oral Quantity | Metformin | Dipeptidyl Peptidase 4 Inhibitors | Sulfonylurea | Glinide | alpha-Glucosidase Inhibitors | Diabetes Therapy Dose Stable
Item
- - currently treated with iglar (insulin glargine) and up to 3 oral antidiabetic drugs (oads) (metformin, dpp-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase inhibitor). all antidiabetic treatments should have been ongoing for at least 12 weeks prior to visit 2 (randomisation) and doses should have been stable in this period of time
boolean
C0907402 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0025598 (UMLS CUI [3])
C2917254 (UMLS CUI [4])
C0038766 (UMLS CUI [5])
C2266929 (UMLS CUI [6])
C1299007 (UMLS CUI [7])
C3274787 (UMLS CUI [8,1])
C0178602 (UMLS CUI [8,2])
C0205360 (UMLS CUI [8,3])
Hemoglobin A1c measurement
Item
- - glycosylated haemoglobin (hba1c) 7.0-10.0% (both inclusive) by central laboratory analysis
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
- - body mass index (bmi) below or equal to 40 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
GLP-1 Receptor Agonist | Thiazolidinediones
Item
- - treatment with glucagon-like peptide 1 (glp-1) receptor agonists or thiazolidinediones (tzds) both within the last 12 weeks prior to visit 2 (randomisation)
boolean
C2917359 (UMLS CUI [1])
C1257987 (UMLS CUI [2])
Cerebrovascular accident | Heart failure New York Heart Association Classification | Myocardial Infarction | Angina, Unstable | Coronary Artery Bypass Surgery | Angioplasty
Item
- - stroke; heart failure new york heart association (nyha) class iii or iv; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 24 weeks prior to visit 2 (randomisation)
boolean
C0038454 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0010055 (UMLS CUI [5])
C0162577 (UMLS CUI [6])
Uncontrolled hypertension Severe | Severe hypertension Untreated | Systolic Pressure | Diastolic blood pressure
Item
- - uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmhg and/or diastolic blood pressure above or equal to 100 mmhg
boolean
C1868885 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C4013784 (UMLS CUI [2,1])
C0332155 (UMLS CUI [2,2])
C0871470 (UMLS CUI [3])
C0428883 (UMLS CUI [4])
Recurrent severe hypoglycemia | Hypoglycaemic episode Severe Quantity | Loss of hypoglycemic warning
Item
- - recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12 months) or hypoglycaemic unawareness as judged by the investigator
boolean
C0342316 (UMLS CUI [1])
C0745153 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0342317 (UMLS CUI [3])
Life threatening illness | Malignant Neoplasms
Item
- - life-threatening disease (e.g. cancer)
boolean
C3846017 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial